Published in J Neurol on April 01, 2000
Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models. Dis Model Mech (2009) 2.16
Dopaminergic regeneration by neurturin-overexpressing c17.2 neural stem cells in a rat model of Parkinson's disease. Mol Neurodegener (2007) 1.42
The neuroprotective functions of selenoprotein M and its role in cytosolic calcium regulation. Antioxid Redox Signal (2010) 1.05
Oxidative and non-oxidative mechanisms of neuronal cell death and apoptosis by L-3,4-dihydroxyphenylalanine (L-DOPA) and dopamine. Br J Pharmacol (2002) 0.98
Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson's disease. Mol Neurodegener (2009) 0.95
Nonselenium glutathione peroxidase in human brain : elevated levels in Parkinson's disease and dementia with lewy bodies. Am J Pathol (2002) 0.95
Parkinson disease-associated DJ-1 is required for the expression of the glial cell line-derived neurotrophic factor receptor RET in human neuroblastoma cells. J Biol Chem (2010) 0.95
Dopaminergic function in a family with the PARK6 form of autosomal recessive Parkinson's syndrome. J Neural Transm (Vienna) (2005) 0.94
Investigations of differences in iron oxidation state inside single neurons from substantia nigra of Parkinson's disease and control patients using the micro-XANES technique. J Biol Inorg Chem (2006) 0.89
Neuroprotective effect of thymoquinone, the nigella sativa bioactive compound, in 6-hydroxydopamine-induced hemi-parkinsonian rat model. Iran J Pharm Res (2014) 0.86
Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers. J Med Chem (2013) 0.84
Selective susceptibility of human dopaminergic neural stem cells to dopamine-induced apoptosis. Exp Neurobiol (2010) 0.83
Cytotoxicity of dopaminochrome in the mesencephalic cell line, MN9D, is dependent upon oxidative stress. Neurotoxicology (2009) 0.82
Autologous transplantation of GDNF-expressing mesenchymal stem cells protects against MPTP-induced damage in cynomolgus monkeys. Sci Rep (2013) 0.77
Why is nitric oxide important for our brain? Funct Neurol (2016) 0.76
Dopaminochrome induces caspase-independent apoptosis in the mesencephalic cell line, MN9D. J Neurochem (2012) 0.76
Terminalia arjuna's antioxidant effect in isolated perfused kidney. Res Pharm Sci (2012) 0.76
Basic studies on epigenetic carcinogenesis of low-dose exposure to 1-trichloromethyl-1,2,3,4-tetrahydro-β-carboline (TaClo) in vitro. PLoS One (2017) 0.75
Berberine chloride pretreatment exhibits neuroprotective effect against 6-hydroxydopamine-induced neuronal insult in rat. Iran J Pharm Res (2015) 0.75
Allelic variation of human serotonin transporter gene expression. J Neurochem (1996) 7.08
AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. Pharmacopsychiatry (2011) 2.91
Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett (1994) 2.27
Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett (1995) 2.19
Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett (1994) 2.17
Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm (1988) 2.10
CNTF and endogenous psychoses? Nat Genet (1996) 2.02
Organization of the human serotonin transporter gene. J Neural Transm Gen Sect (1994) 1.97
Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J Neural Transm (Vienna) (1998) 1.90
Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J Neural Transm (Vienna) (2004) 1.89
Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study. J Neural Transm (1985) 1.89
Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: prado-study discontinued. Eur J Clin Pharmacol (1992) 1.86
Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am J Pathol (2001) 1.81
Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem (1991) 1.70
The 5-HT transporter gene-linked polymorphic region (5-HTTLPR) in evolutionary perspective: alternative biallelic variation in rhesus monkeys. Rapid communication. J Neural Transm (Vienna) (1997) 1.65
The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry (2004) 1.64
The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil. J Neural Transm (1975) 1.62
Human brain dopamine receptors in children and aging adults. Synapse (1987) 1.55
Brain iron pathways and their relevance to Parkinson's disease. J Neurochem (2001) 1.55
Time course of nigrostriatal degeneration in parkinson's disease. A detailed study of influential factors in human brain amine analysis. J Neural Transm (1976) 1.54
Borna disease virus in human brains with a rare form of hippocampal degeneration but not in brains of patients with common neuropsychiatric disorders. J Infect Dis (1999) 1.53
Cell death and apoptosis regulating proteins in Parkinson's disease--a cautionary note. Acta Neuropathol (1999) 1.48
Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem (1994) 1.46
Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm (Vienna) (1996) 1.45
Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett (1992) 1.44
N-methyl-(R)-salsolinol and its relevance to Parkinson's disease. Lancet (1998) 1.40
Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study. Lancet (1977) 1.38
Progressive supranuclear palsy: clinico-pathological and biochemical studies. J Neural Transm Suppl (1980) 1.38
Brain-derived neurotrophic factor and neurotrophin 3 in schizophrenic psychoses. Schizophr Res (2001) 1.37
Neuromelanin in human dopamine neurons: comparison with peripheral melanins and relevance to Parkinson's disease. Prog Neurobiol (2005) 1.37
Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer's disease. J Alzheimers Dis (2007) 1.36
Alzheimer's disease--synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. J Neural Transm (Vienna) (1998) 1.35
Oxidative stress: free radical production in neural degeneration. Pharmacol Ther (1994) 1.33
Iron, neuromelanin and ferritin content in the substantia nigra of normal subjects at different ages: consequences for iron storage and neurodegenerative processes. J Neurochem (2001) 1.33
Bimodal distribution of dopamine receptor densities in brains of schizophrenics. Science (1984) 1.28
Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J Neural Transm Park Dis Dement Sect (1990) 1.27
High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. J Neural Transm (Vienna) (2004) 1.26
Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder. Neurotox Res (2006) 1.26
Serotonin, noradrenaline, dopamine metabolites in transcendental meditation-technique. J Neural Transm (1976) 1.26
Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol (1991) 1.26
Impaired phosphorylation of cyclic AMP response element binding protein in the hippocampus of dementia of the Alzheimer type. Brain Res (1999) 1.24
Functional promoter and polyadenylation site mapping of the human serotonin (5-HT) transporter gene. J Neural Transm Gen Sect (1995) 1.23
Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA. Eur J Clin Chem Clin Biochem (1997) 1.21
Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. Neuropsychopharmacology (1987) 1.20
Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum. J Neural Transm (Vienna) (2003) 1.18
The possible role of iron in the etiopathology of Parkinson's disease. Mov Disord (1993) 1.15
MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur J Pharmacol (1991) 1.13
Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm Suppl (1994) 1.11
Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease. Neurosci Lett (1994) 1.10
Neuronal and glial coexpression of argininosuccinate synthetase and inducible nitric oxide synthase in Alzheimer disease. J Neuropathol Exp Neurol (2001) 1.10
Human post-mortem striatal alpha4beta2 nicotinic acetylcholine receptor density in schizophrenia and Parkinson's syndrome. Neurosci Lett (2000) 1.10
Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour. Mol Pathol (2001) 1.09
Insulin-degrading enzyme in the Alzheimer's disease brain: prominent localization in neurons and senile plaques. Neurosci Lett (1999) 1.08
How a neuropsychiatric brain bank should be run: a consensus paper of Brainnet Europe II. J Neural Transm (Vienna) (2006) 1.07
Diagnostic staging of Parkinson's disease: conceptual aspects. J Neural Transm (Vienna) (2004) 1.06
Age-dependent memory loss, synaptic pathology and altered brain plasticity in the Drosophila mutant cardinal accumulating 3-hydroxykynurenine. J Neural Transm (Vienna) (2000) 1.06
Cytotoxicity of advanced glycation endproducts is mediated by oxidative stress. J Neural Transm (Vienna) (1998) 1.06
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level. Brain Res (1996) 1.06
Parkinson's disease and depression: evidence for an alteration of the basal limbic system detected by transcranial sonography. J Neurol Neurosurg Psychiatry (1997) 1.05
Allelic variation of serotonin transporter expression is associated with depression in Parkinson's disease. Mol Psychiatry (2001) 1.05
On the mode of action of L-deprenyl in the human central nervous system. J Neural Transm (1978) 1.05
Primary structure of the serotonin transporter in unipolar depression and bipolar disorder. Biol Psychiatry (1995) 1.04
Iron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis. J Neurochem (1992) 1.04
Isolation of a cDNA encoding the human brain serotonin transporter. J Neural Transm Gen Sect (1993) 1.03
Potential sources of increased iron in the substantia nigra of parkinsonian patients. J Neural Transm Suppl (2006) 1.03
High molecular weight hyaluronic acid inhibits advanced glycation endproduct-induced NF-kappaB activation and cytokine expression. FEBS Lett (1999) 1.03
Distinction between benign and malignant type of Parkinson's disease. Clin Neurol Neurosurg (1979) 1.03
Dementia in Parkinson's disease and (pre) senile dementia of Alzheimer type: morphological aspects and changes in the intracerebral MAO activity. Adv Neurol (1984) 1.03
A disturbance in the neuronal insulin receptor signal transduction in sporadic Alzheimer's disease. Ann N Y Acad Sci (1999) 1.03
Advanced glycation endproducts in ageing and Alzheimer's disease. Brain Res Brain Res Rev (1997) 1.02
Parkinsonism in HIV dementia. J Neural Transm (Vienna) (2002) 1.02
Iron in brain function and dysfunction with emphasis on Parkinson's disease. Eur Neurol (1991) 1.02
Microglia activation is related to substantia nigra echogenicity. J Neural Transm (Vienna) (2010) 1.01
AGES in brain ageing: AGE-inhibitors as neuroprotective and anti-dementia drugs? Biogerontology (2001) 1.01
Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur J Pharmacol (1989) 1.01
Enhancement of central nervous system pathology in early simian immunodeficiency virus infection by dopaminergic drugs. Acta Neuropathol (2001) 1.00
Crosslinking of alpha-synuclein by advanced glycation endproducts--an early pathophysiological step in Lewy body formation? J Chem Neuroanat (2000) 1.00
Far field potentials from the brain stem after transcutaneous vagus nerve stimulation. J Neural Transm (Vienna) (2003) 1.00
Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration? Acta Neurol Scand Suppl (1989) 0.99
Potential genetic markers of sporadic Alzheimer's dementia. Psychiatr Genet (2001) 0.99
Brain-derived neurotrophic factor and neurotrophin-3 levels in Alzheimer's disease brains. Int J Dev Neurosci (2000) 0.99
Iron accumulation in the substantia nigra in rats visualized by ultrasound. Ultrasound Med Biol (1999) 0.99
Reduced phosphorylation of cyclic AMP-responsive element binding protein in the postmortem orbitofrontal cortex of patients with major depressive disorder. J Neural Transm (Vienna) (2003) 0.99
Glutamate receptor antagonists for neuroleptic malignant syndrome and akinetic hyperthermic parkinsonian crisis. J Neural Transm Park Dis Dement Sect (1993) 0.98
Involvement of dopamine in the progression of AIDS Dementia Complex. J Neural Transm (Vienna) (2002) 0.98
Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl. J Neurochem (1986) 0.98
Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease. J Neurochem (1991) 0.98
Brain monoamines in human hepatic encephalopathy. Acta Neuropathol (1978) 0.98
Persistence of haloperidol in human brain tissue. Am J Psychiatry (1999) 0.98
The effect of simian immunodeficiency virus infection in vitro and in vivo on the cytokine production of isolated microglia and peripheral macrophages from rhesus monkey. Virology (1996) 0.97
Understanding Parkinson's disease. Sci Am (1997) 0.96
Pretreatment with nimodipine prevents MPTP-induced neurotoxicity at the nigral, but not at the striatal level in mice. Neuroreport (1995) 0.95
Quantification of mRNA of tyrosine hydroxylase and aromatic L-amino acid decarboxylase in the substantia nigra in Parkinson's disease and schizophrenia. J Neural Transm Park Dis Dement Sect (1994) 0.95
A promoter-associated polymorphic repeat modulates PAX-6 expression in human brain. Biochem Biophys Res Commun (1998) 0.95
Nitroxyl oxidizes NADPH in a superoxide dismutase inhibitable manner. Free Radic Biol Med (2001) 0.94
Alpha-lipoic acid as a new treatment option for Alzheimer [corrected] type dementia. Arch Gerontol Geriatr (2001) 0.94
Abnormal localization of two neuronal calcium sensor proteins, visinin-like proteins (vilips)-1 and -3, in neocortical brain areas of Alzheimer disease patients. Dement Geriatr Cogn Disord (2001) 0.94
Increased dopaminergic neurotransmission in therapy-naïve asymptomatic HIV patients is not associated with adaptive changes at the dopaminergic synapses. J Neural Transm (Vienna) (2010) 0.94
Regulation of PAX-6 gene transcription: alternate promoter usage in human brain. Brain Res Mol Brain Res (1998) 0.93